Want to see SE:IRLAB.A full AI Analyst Report?
Top Page
IRLAB Therapeutics AB Class A
(IRLAB.A)
Select Model
Select Model
Rating:52Neutral
Price Target:
kr2.00
▼(-0.50% Downside)
Action:Reiterated
Date:08/28/26
The score is held back primarily by weak financial performance (deep losses, contracting revenue, and ongoing cash burn), partially offset by a de-risked balance sheet. Technicals are a near-term positive with the stock trading above key moving averages and positive MACD, but valuation remains unattractive/unclear due to negative earnings and no dividend yield data.
Positive Factors
Improved Balance Sheet
Leverage has improved materially from prior years, reducing balance-sheet pressure and providing greater financial flexibility. The roughly 0.25 debt-to-equity ratio and approximately 97M of equity offer a stronger cushion while IRLAB continues funding clinical development.
Negative Factors
Deep Unprofitability
Deep losses and negative gross profit show that the current revenue base does not cover IRLAB’s operating and development costs. Contracting revenue further weakens operating leverage, leaving profitability dependent on successful pipeline progress and future revenue growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Balance Sheet
Leverage has improved materially from prior years, reducing balance-sheet pressure and providing greater financial flexibility. The roughly 0.25 debt-to-equity ratio and approximately 97M of equity offer a stronger cushion while IRLAB continues funding clinical development.
Read all positive factors
IRLAB Therapeutics AB Class A (IRLAB.A) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr300.40M
Dividend YieldN/A
Average Volume (3M)699.97K
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue Growth4.74%
EPS Growth66.33%
CountrySE
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.65
Shares Outstanding148,632,140
10 Day Avg. Volume850,021
30 Day Avg. Volume699,969
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)4.30
Price to Sales (P/S)2.30
P/FCF Ratio-2.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.57
Revenue Forecast (FY)kr102.00M
IRLAB Therapeutics AB Class A Business Overview & Revenue Model
Company Description
IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepema...
How the Company Makes Money
IRLAB Therapeutics primarily generates revenue through collaboration and partnering arrangements for its drug candidates, which can include upfront payments, research funding, development and regulatory milestone payments, and royalties on future ...
IRLAB Therapeutics AB Class A Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 79.33M | 57.46M | 94.63M | 5.68M | 61.14M | 207.78M |
| Gross Profit | -46.31M | -92.35M | -92.42M | -122.73M | -111.23M | 168.69M |
| EBITDA | -40.55M | -88.03M | -68.07M | -173.32M | -109.13M | 56.05M |
| Net Income | -53.84M | -110.01M | -83.13M | -177.84M | -114.20M | 51.78M |
Balance Sheet | ||||||
| Total Assets | 182.37M | 138.21M | 136.21M | 177.12M | 323.56M | 472.45M |
| Cash, Cash Equivalents and Short-Term Investments | 34.22M | 81.86M | 66.92M | 111.31M | 252.78M | 401.90M |
| Total Debt | 24.20M | 29.95M | 60.42M | 27.57M | 3.98M | 6.60M |
| Total Liabilities | 85.24M | 107.49M | 103.58M | 61.36M | 32.72M | 72.97M |
| Stockholders Equity | 97.13M | 30.72M | 32.63M | 115.76M | 290.83M | 399.48M |
Cash Flow | ||||||
| Free Cash Flow | -61.05M | -55.22M | -65.79M | -165.14M | -145.99M | 127.93M |
| Operating Cash Flow | -61.05M | -55.22M | -65.59M | -164.85M | -142.61M | 128.64M |
| Investing Cash Flow | 0.00 | 0.00 | -199.00K | -293.00K | -3.38M | -708.00K |
| Financing Cash Flow | 42.65M | 73.41M | 21.40M | 23.68M | -3.13M | -3.04M |
IRLAB Therapeutics AB Class A Technical Analysis
Positive
2.01
Price Trends
1.82
Positive
1.58
Positive
1.55
Positive
Market Momentum
0.06
Negative
55.25
Neutral
55.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IRLAB.A, the sentiment is Positive. The current price of 2.01 is above the 20-day moving average (MA) of 1.89, above the 50-day MA of 1.82, and above the 200-day MA of 1.55, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 55.25 is Neutral, neither overbought nor oversold. The STOCH value of 55.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IRLAB.A.
IRLAB Therapeutics AB Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | kr27.85B | 263.70 | 5.18% | 0.68% | -46.09% | -90.13% | |
68 Neutral | kr1.49B | 8.07 | 29.71% | ― | 24.98% | -31.44% | |
52 Neutral | kr300.40M | -3.11 | -97.06% | ― | 4.74% | 66.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr890.82M | 43.27 | 65.99% | ― | ― | ― | |
49 Neutral | kr1.01B | -9.14 | -58.12% | ― | ― | 1.42% | |
44 Neutral | kr118.84M | -1.83 | -17.52% | ― | -100.00% | 20.94% |
* Healthcare Sector Average
SE:IRLAB.A
IRLAB Therapeutics AB Class A
2.02
-0.25
-11.21%
SE:ALZ
Alzinova AB
0.39
-1.15
-74.85%
SE:ALZCUR
AlzeCure Pharma AB
6.46
4.60
248.06%
SE:BIOA.B
BioArctic AB Class B
313.80
21.93
7.51%
SE:SYNACT
SynAct Pharma AB
18.00
-3.50
-16.28%
SE:SANION
Saniona AB
10.81
-3.89
-26.46%
IRLAB Therapeutics AB Class A Corporate Events
IRLAB Wins Key U.S. Patent Boost for Next-Generation Parkinson’s Drug IRL1117
Oct 27, 2026
IRLAB Therapeutics AB, a Gothenburg-based biopharmaceutical company listed on Nasdaq Stockholm, specializes in developing new treatments for Parkinson’s disease across all stages of the illness. Built on research from Nobel Laureate Prof. Ar...
IRLAB names nomination committee ahead of 2027 AGM
Oct 20, 2026
IRLAB Therapeutics has appointed a nomination committee for its 2027 annual general meeting, in line with a mandate approved by shareholders in 2024. The committee includes representatives of the three largest shareholder groups as of late August ...
IRLAB Research on Potential First-in-Class Apathy Drug Linepemat Published
Oct 20, 2026
IRLAB Therapeutics said the preclinical research underpinning its investigational drug linepemat, also known as IRL757, has been published in the peer-reviewed journal Bioorganic Medicinal Chemistry Letters. The molecule was designed to enhance a...
IRLAB to Spotlight Parkinson’s Pipeline at Redeye Neurology Event
Oct 9, 2026
IRLAB Therapeutics AB, a Stockholm-listed biopharma group specializing in novel Parkinson’s disease therapies, is advancing multiple candidates including Mesdopetam, which has completed Phase IIb for levodopa-induced dyskinesias and is being...
IRLAB Therapeutics Names Janne Backman as Chairman to Steer Parkinson’s Pipeline and Partnerships
Sep 24, 2026
IRLAB Therapeutics AB, a Nasdaq Stockholm-listed biopharmaceutical group based in Gothenburg, develops novel Parkinson’s disease therapies from early research through late-stage clinical trials, leveraging a proprietary systems biology platf...
IRLAB CEO to Step Down in 2027 as Parkinson’s Pipeline Advances
Sep 3, 2026
IRLAB Therapeutics’ chief executive Kristina Torfgård has informed the board she intends to step down during the first quarter of 2027, though she will remain in place to ensure a smooth handover while the board launches an immediate se...
IRLAB Therapeutics Updates Share Capital After Completed Rights Issue
Aug 31, 2026
IRLAB Therapeutics AB has updated its share capital structure following the completion of a rights issue and an overallotment issue of ordinary shares of series A, resolved by the board in May and approved by an extraordinary general meeting in Ju...
IRLAB strengthens Parkinson’s pipeline and finances in Q2 2026
Aug 26, 2026
IRLAB reported second-quarter 2026 net sales of SEK 6.4 million, down from SEK 19.5 million a year earlier, and an operating loss of SEK 16.7 million, while earnings per share improved to a loss of SEK 0.23 versus SEK 0.62. The company’s rig...
IRLAB to Webcast Q2 2026 Interim Report as Parkinson’s Pipeline Advances
Aug 20, 2026
IRLAB Therapeutics AB, a Gothenburg-based biotech specializing in novel Parkinson’s disease therapies, is advancing a diversified clinical and preclinical pipeline built on its proprietary systems biology-based research platform. With multip...
WHO Grants INN Name to IRLAB’s Apathy Drug Candidate Linepemat
Aug 19, 2026
IRLAB Therapeutics AB, a Gothenburg-based biopharmaceutical company specializing in Parkinson’s disease and other neurodegenerative disorders, is building a diversified pipeline of small-molecule drug candidates addressing motor complication...
IRLAB Updates Share Capital After Rights Issue to Support Parkinson’s Pipeline
Jul 31, 2026
IRLAB Therapeutics AB is a Swedish biopharmaceutical company focused on discovering and developing transformative treatments for all stages of Parkinson’s disease and related neurodegenerative disorders. Originating from Nobel Laureate Arvid...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.